Cardiovascular effects of green tea catechins: Progress and promise

Recent Patents on Cardiovascular Drug Discovery

Volumn 7, Issue 2, 2012, Pages 88-99

  Islam, Mohammed A ^a  

^a LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Anti inflammatory; Antioxidant; Atherosclerosis; EGCG; Endothelial dysfunction; Green tea catechins; HDL cholesterol; LDL cholesterol

Indexed keywords

CATECHOL; CATHECHIN PLUS THEAFLAVIN; EPICATECHIN; EPIGALLOCATECHIN GALLATE; FLAVONOID; GREEN TEA EXTRACT; PLACEBO; POLYPHENON; POLYPHENON E; THEAFLAVIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CELL PROLIFERATION; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TEA;

ANIMALS; ANTIOXIDANTS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CATECHIN; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION; MODELS, CARDIOVASCULAR; PLATELET AGGREGATION; SIGNAL TRANSDUCTION; TEA;

EID: 84863543743     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489012801227292     Document Type: Review

References (185)

1. McKay DL, Blumberg JB. The role of tea in human health: An update. J Am Coll Nutr 2002; 21: 1-13.
2. Sato T, Miyata G. The nutraceutical benefit, part I: Green tea. Nutrition 2000; 16: 315-7.
3. Mak JC. Potential role of green tea catechins in various disease therapies: Progress and promise. Clin Exp Pharmacol Physiol 2012; 39: 265-73.
4. Erdman JW, Jr., Balentine D, Arab L, Beecher G, Dwyer JT, Folts J, et al. Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. J Nutr 2007; 137: 718S-37S.
5. Khokhar S, Magnusdottir SG. Total phenol, catechin, and caffeine contents of teas commonly consumed in the United kingdom. J Agric Food Chem 2002; 50: 565-70.
6. Lin YS, Tsai YJ, Tsay JS, Lin JK. Factors affecting the levels of tea polyphenols and caffeine in tea leaves. J Agric Food Chem 2003; 51: 1864-73.
7. Sabhapondit S, Karak T, Bhuyan LP, Goswami BC, Hazarika M. Diversity of catechin in northeast Indian tea cultivars. Scientific World Journal; 2012: 485193.
8. Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992; 21: 334-50.
9. Chacko SM, Thambi PT, Kuttan R, Nishigaki I. Beneficial effects of green tea: a literature review. Chin Med 2010; 2010; 5: 13.
10. Sano M, Tabata M, Suzuki M, Degawa M, Miyase T, Maeda- Yamamoto M. Simultaneous determination of twelve tea catechins by high-performance liquid chromatography with electrochemical detection. Analyst 2001; 126: 816-20.
11. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 1997; 37: 693-704.
12. WHO. Global atlas on cardiovascular disease prevention and control. Editors: WHO; World Heart Federation; World Stroke Organization 2011.
13. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.
14. Vita JA, Keaney JF, Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106: 640-2.
15. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009; 6: 399-409.
16. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Jr., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-25.
17. Wojakowski W, Gminski J. Soluble ICAM-1, VCAM-1 and Eselectin in children from families with high risk of atherosclerosis. Int J Mol Med 2001; 7: 181-5.
18. Brevetti G, Martone VD, de Cristofaro T, Corrado S, Silvestro A, Di Donato AM, et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001; 85: 63-6.
19. Fichtlscherer S, Breuer S, Schachinger V, Dimmeler S, Zeiher AM. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 2004; 25: 1412-8.
20. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-6.
21. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
22. Blann AD. Is raised von Willebrand factor a marker of endothelial cell damage? Med Hypotheses 1993; 41: 419-24.
23. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100: 1161-8.
24. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J 2002; 66: 529-33.
25. Babu PV, Liu D. Green tea catechins and cardiovascular health: an update. Curr Med Chem 2008; 15: 1840-50.
26. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 2007; 26: 373S-88S.
27. Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol 2001; 154: 495-503.
28. Keli SO, Hertog MG, Feskens EJ, Kromhout D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med 1996; 156: 637-42.
29. Arts IC, Hollman PC, Feskens EJ, Bueno de Mesquita HB, Kromhout D. Catechin intake might explain the inverse relation between tea consumption and ischemic heart disease: the Zutphen Elderly Study. Am J Clin Nutr 2001; 74: 227-32.
30. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006; 296: 1255-65.
31. Cabrera C, Artacho R, Gimenez R. Beneficial effects of green tea a review. J Am Coll Nutr 2006; 25: 79-99.
32. Stangl V, Dreger H, Stangl K, Lorenz M. Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res 2007; 73: 348-58.
33. Suzuki J, Isobe M, Morishita R, Nagai R. Tea polyphenols regulate key mediators on inflammatory cardiovascular diseases. Mediators Inflamm 2009; 2009: 494928.
34. Tokunaga S, White IR, Frost C, Tanaka K, Kono S, Tokudome S, et al. Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Ann Epidemiol 2002; 12: 157-65.
35. Hollman PC, Feskens EJ, Katan MB. Tea flavonols in cardiovascular disease and cancer epidemiology. Proc Soc Exp Biol Med 1999; 220: 198-202.
36. Kuriyama S. The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies. J Nutr 2008; 138: 1548S-53S.
37. Kuriyama S. Green tea consumption and prevention of coronary artery disease. Circ J 2010; 74: 248-9.
38. Sasazuki S, Kodama H, Yoshimasu K, Liu Y, Washio M, Tanaka K, et al. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Ann Epidemiol 2000; 10: 401-8.
39. Suzuki E, Yorifuji T, Takao S, Komatsu H, Sugiyama M, Ohta T, et al. Green tea consumption and mortality among Japanese elderly people: the prospective Shizuoka elderly cohort. Ann Epidemiol 2009; 19: 732-9.
40. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 2000; 13: 49-54.
41. Sano J, Inami S, Seimiya K, Ohba T, Sakai S, Takano T, et al. Effects of green tea intake on the development of coronary artery disease. Circ J 2004; 68: 665-70.
42. Wang QM, Gong QY, Yan JJ, Zhu J, Tang JJ, Wang MW, et al. Association between green tea intake and coronary artery disease in a Chinese population. Circ J 2010; 74: 294-300.
43. Miller RJ, Jackson KG, Dadd T, Mayes AE, Brown AL, Minihane AM. The impact of the catechol-O-methyltransferase genotype on the acute responsiveness of vascular reactivity to a green tea extract. Br J Nutr; 105: 1138-44.
44. Frank J, George TW, Lodge JK, Rodriguez-Mateos AM, Spencer JP, Minihane AM, et al. Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. J Nutr 2009; 139: 58-62.
45. Grassi D, Aggio A, Onori L, Croce G, Tiberti S, Ferri C, et al. Tea, flavonoids, and nitric oxide-mediated vascular reactivity. J Nutr 2008; 138: 1554S-60S.
46. Alexopoulos N, Vlachopoulos C, Aznaouridis K, Baou K, Vasiliadou C, Pietri P, et al. The acute effect of green tea consumption on endothelial function in healthy individuals. Eur J Cardiovasc Prev Rehabil 2008; 15: 300-5.
47. Tinahones FJ, Rubio MA, Garrido-Sanchez L, Ruiz C, Gordillo E, Cabrerizo L, et al. Green tea reduces LDL oxidability and improves vascular function. J Am Coll Nutr 2008; 27: 209-13.
48. Kim W, Jeong MH, Cho SH, Yun JH, Chae HJ, Ahn YK, et al. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J 2006; 70: 1052-7.
49. Loke WM, Hodgson JM, Proudfoot JM, McKinley AJ, Puddey IB, Croft KD. Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr 2008; 88: 1018-25.
50. Oyama J, Maeda T, Kouzuma K, Ochiai R, Tokimitsu I, Higuchi Y, et al. Green tea catechins improve human forearm endothelial dysfunction and have antiatherosclerotic effects in smokers. Circ J 2010; 74: 578-88.
51. Hodgson JM, Puddey IB, Burke V, Croft KD. Is reversal of endothelial dysfunction by tea related to flavonoid metabolism? Br J Nutr 2006; 95: 14-7.
52. Duffy SJ, Keaney JF, Jr., Holbrook M, Gokce N, Swerdloff PL, Frei B, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001; 104: 151-6.
53. Hodgson JM. Effects of tea and tea flavonoids on endothelial function and blood pressure: a brief review. Clin Exp Pharmacol Physiol 2006; 33: 838-41.
54. Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg Med Chem 2007; 15: 4674-99.
55. Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ 1995; 310: 693-6.
56. Zheng XX, Xu YL, Li SH, Liu XX, Hui R, Huang XH. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr 2011; 94: 601-10.
57. Hirano-Ohmori R, Takahashi R, Momiyama Y, Taniguchi H, Yonemura A, Tamai S, et al. Green tea consumption and serum malondialdehyde-modified LDL concentrations in healthy subjects. J Am Coll Nutr 2005; 24: 342-6.
58. Gomikawa S, Ishikawa Y, Hayase W, Haratake Y, Hirano N, Matuura H, et al. Effect of ground green tea drinking for 2 weeks on the susceptibility of plasma and LDL to the oxidation ex vivo in healthy volunteers. Kobe J Med Sci 2008; 54: E62-72.
59. Kim A, Chiu A, Barone MK, Avino D, Wang F, Coleman CI, et al. Green tea catechins decrease total and low-density lipoprotein cholesterol: A systematic review and meta-analysis. J Am Diet Assoc; 111: 1720-9.
60. Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P. Effect of green tea extract on obese women: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 2008; 27: 363-70.
61. Nagao T, Hase T, Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 2007; 15: 1473-83.
62. Wu AH, Spicer D, Stanczyk FZ, Tseng CC, Yang CS, Pike MC. Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women. Cancer Prev Res (Phila) 2012; 5: 393-402.
63. Inami S, Takano M, Yamamoto M, Murakami D, Tajika K, Yodogawa K, et al. Tea catechin consumption reduces circulating oxidized low-density lipoprotein. Int Heart J 2007; 48: 725-32.
64. Erba D, Riso P, Bordoni A, Foti P, Biagi PL, Testolin G. Effectiveness of moderate green tea consumption on antioxidative status and plasma lipid profile in humans. J Nutr Biochem 2005; 16: 144-9.
65. Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr 2010; 29: 31-40.
66. Eichenberger P, Colombani PC, Mettler S. Effects of 3-week consumption of green tea extracts on whole-body metabolism during cycling exercise in endurance-trained men. Int J Vitam Nutr Res 2009; 79: 24-33.
67. Trautwein EA, Du Y, Meynen E, Yan X, Wen Y, Wang H, et al. Purified black tea theaflavins and theaflavins/catechin supplements did not affect serum lipids in healthy individuals with mildly to moderately elevated cholesterol concentrations. Eur J Nutr 2010; 49: 27-35.
68. Stensvold I, Tverdal A, Solvoll K, Foss OP. Tea consumption. relationship to cholesterol, blood pressure, and coronary and total mortality. Prev Med 1992; 21: 546-53.
69. Wakabayashi K, Kono S, Shinchi K, Honjo S, Todoroki I, Sakurai Y, et al. Habitual coffee consumption and blood pressure: A study of self-defense officials in Japan. Eur J Epidemiol 1998; 14: 669-73.
70. Yang YC, Lu FH, Wu JS, Wu CH, Chang CJ. The protective effect of habitual tea consumption on hypertension. Arch Intern Med 2004; 164: 1534-40.
71. Hodgson JM, Devine A, Puddey IB, Chan SY, Beilin LJ, Prince RL. Tea intake is inversely related to blood pressure in older women. J Nutr 2003; 133: 2883-6.
72. Brown AL, Lane J, Coverly J, Stocks J, Jackson S, Stephen A, et al. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr 2009; 101: 886-94.
73. Brown AL, Lane J, Holyoak C, Nicol B, Mayes AE, Dadd T. Health effects of green tea catechins in overweight and obese men: A randomised controlled cross-over trial. Br J Nutr 2011; 106: 1880-9.
74. Potenza MA, Marasciulo FL, Tarquinio M, Tiravanti E, Colantuono G, Federici A, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 2007; 292: E1378-87.
75. Sanae F, Miyaichi Y, Kizu H, Hayashi H. Effects of catechins on vascular tone in rat thoracic aorta with endothelium. Life Sci 2002; 71: 2553-62.
76. Lim DY, Lee ES, Park HG, Kim BC, Hong SP, Lee EB. Comparison of green tea extract and epigallocatechin gallate on blood pressure and contractile responses of vascular smooth muscle of rats. Arch Pharm Res 2003; 26: 214-23.
77. Ihm SH, Lee JO, Kim SJ, Seung KB, Schini-Kerth VB, Chang K, et al. Catechin prevents endothelial dysfunction in the prediabetic stage of OLETF rats by reducing vascular NADPH oxidase activity and expression. Atherosclerosis 2009; 206: 47-53.
78. Igarashi K, Honma K, Yoshinari O, Nanjo F, Hara Y. Effects of dietary catechins on glucose tolerance, blood pressure and oxidative status in Goto-Kakizaki rats. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 496-500.
79. Antonello M, Montemurro D, Bolognesi M, Di Pascoli M, Piva A, Grego F, et al. Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. Am J Hypertens 2007; 20: 1321-8.
80. Papparella I, Ceolotto G, Montemurro D, Antonello M, Garbisa S, Rossi G, et al. Green tea attenuates angiotensin II-induced cardiac hypertrophy in rats by modulating reactive oxygen species production and the Src/epidermal growth factor receptor/Akt signaling pathway. J Nutr 2008; 138: 1596-601.
81. Verschuren L, Wielinga PY, van Duyvenvoorde W, Tijani S, Toet K, van Ommen B, et al. A dietary mixture containing fish oil, resveratrol, lycopene, catechins, and vitamins E and C reduces atherosclerosis in transgenic mice. J Nutr 2011; 141: 863-9.
82. Miura Y, Chiba T, Tomita I, Koizumi H, Miura S, Umegaki K, et al. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutr 2001; 131: 27-32.
83. Chyu KY, Babbidge SM, Zhao X, Dandillaya R, Rietveld AG, Yano J, et al. Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein Enull mice. Circulation 2004; 109: 2448-53.
84. Hirase T, Node K. Endothelial dysfunction as a cellular mechanism for vascular failure. Am J Physiol Heart Circ Physiol 2012; 302: H499-505.
85. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003; 93: 388-98.
86. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-95.
87. Vita JA. Endothelial function. Circulation 2011; 124: e906-12.
88. Jochmann N, Lorenz M, Krosigk A, Martus P, Bohm V, Baumann G, et al. The efficacy of black tea in ameliorating endothelial function is equivalent to that of green tea. Br J Nutr 2008; 99: 863-8.
89. Lorenz M, Wessler S, Follmann E, Michaelis W, Dusterhoft T, Baumann G, et al. A constituent of green tea, epigallocatechin-3- gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol- 3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem 2004; 279: 6190-5.
90. Benito S, Lopez D, Saiz MP, Buxaderas S, Sanchez J, Puig- Parellada P, et al. A flavonoid-rich diet increases nitric oxide production in rat aorta. Br J Pharmacol 2002; 135: 910-6.
91. Persson IA, Josefsson M, Persson K, Andersson RG. Tea flavanols inhibit angiotensin-converting enzyme activity and increase nitric oxide production in human endothelial cells. J Pharm Pharmacol 2006; 58: 1139-44.
92. Kim JA, Formoso G, Li Y, Potenza MA, Marasciulo FL, Montagnani M, et al. Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn. J Biol Chem 2007; 282: 13736-45.
93. Bourque SL, Davidge ST, Adams MA. The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol 2011; 300: R1288-95.
94. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
95. Gossl M, Lerman A. Endothelin: beyond a vasoconstrictor. Circulation 2006; 113: 1156-8.
96. de Andrade CR, Leite PF, Montezano AC, Casolari DA, Yogi A, Tostes RC, et al. Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia. Br J Pharmacol 2009; 157: 568-80.
97. Zhou J, Zhu Y, Cheng M, Dinesh D, Thorne T, Poh KK, et al. Regulation of vascular contractility and blood pressure by the E2F2 transcription factor. Circulation 2009; 120: 1213-21.
98. Thijssen DH, Rongen GA, van Dijk A, Smits P, Hopman MT. Enhanced endothelin-1-mediated leg vascular tone in healthy older subjects. J Appl Physiol 2007; 103: 852-7.
99. Reiter CE, Kim JA, Quon MJ. Green tea polyphenol epigallocatechin gallate reduces endothelin-1 expression and secretion in vascular endothelial cells: Roles for AMP-activated protein kinase, Akt, and FOXO1. Endocrinology 2010; 151: 103-14.
100. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G. Atherosclerosis as an Inflammatory Disease. Curr Pharm Des 2012: [Epub ahead of print].
101. Kevil CG, Patel RP, Bullard DC. Essential role of ICAM-1 in mediating monocyte adhesion to aortic endothelial cells. Am J Physiol Cell Physiol 2001; 281: C1442-7.
102. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, Jr., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718-23.
103. Ramesh E, Geraldine P, Thomas PA. Regulatory effect of epigallocatechin gallate on the expression of C-reactive protein and other inflammatory markers in an experimental model of atherosclerosis. Chem Biol Interact 2010; 183: 125-32.
104. Wang CJ, Liu JT, Guo F. (-)-epigallocatechin gallate inhibits endothelin- 1-induced C-reactive protein production in vascular smooth muscle cells. Basic Clin Pharmacol Toxicol 2010; 107: 669-75.
105. da Silva CG, Specht A, Wegiel B, Ferran C, Kaczmarek E. Mechanism of purinergic activation of endothelial nitric oxide synthase in endothelial cells. Circulation 2009; 119: 871-9.
106. Ahn HY, Kim CH, Ha TS. Epigallocatechin-3-gallate Regulates NADPH Oxidase Expression in Human Umbilical Vein Endothelial Cells. Korean J Physiol Pharmacol 2010; 14: 325-9.
107. Ludwig A, Lorenz M, Grimbo N, Steinle F, Meiners S, Bartsch C, et al. The tea flavonoid epigallocatechin-3-gallate reduces cytokine- induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 2004; 316: 659-65.
108. Suzuki J, Ogawa M, Izawa A, Sagesaka YM, Isobe M. Dietary consumption of green tea catechins attenuate hyperlipidaemiainduced atherosclerosis and systemic organ damage in mice. Acta Cardiol 2005; 60: 271-6.
109. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17: 3-9.
110. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
111. Hong MH, Kim MH, Chang HJ, Kim NH, Shin BA, Ahn BW, et al. (-)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-kappaB signaling. Life Sci 2007; 80: 1957-65.
112. Ahn HY, Xu Y, Davidge ST. Epigallocatechin-3-O-gallate inhibits TNFalpha-induced monocyte chemotactic protein-1 production from vascular endothelial cells. Life Sci 2008; 82: 964-8.
113. Pullikotil P, Chen H, Muniyappa R, Greenberg CC, Yang S, Reiter CE, et al. Epigallocatechin gallate induces expression of heme oxygenase-1 in endothelial cells via p38 MAPK and Nrf-2 that suppresses proinflammatory actions of TNF-alpha. J Nutr Biochem 2011: [Epub ahead of print].
114. Lambert JD, Elias RJ. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys 2010; 501: 65-72.
115. Ying CJ, Xu JW, Ikeda K, Takahashi K, Nara Y, Yamori Y. Tea polyphenols regulate nicotinamide adenine dinucleotide phosphate oxidase subunit expression and ameliorate angiotensin II-induced hyperpermeability in endothelial cells. Hypertens Res 2003; 26: 823-8.
116. Khan SG, Katiyar SK, Agarwal R, Mukhtar H. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res 1992; 52: 4050-2.
117. Paquay JB, Haenen GR, Stender G, Wiseman SA, Tijburg LB, Bast A. Protection against nitric oxide toxicity by tea. J Agric Food Chem 2000; 48: 5768-72.
118. Abo A, Pick E, Hall A, Totty N, Teahan CG, Segal AW. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991; 353: 668-70.
119. Sakamoto N, Ishibashi T, Sugimoto K, Sawamura T, Sakamoto T, Inoue N, et al. Role of LOX-1 in monocyte adhesion-triggered redox, Akt/eNOS and Ca2+ signaling pathways in endothelial cells. J Cell Physiol 2009; 220: 706-15.
120. Schewe T, Steffen Y, Sies H. How do dietary flavanols improve vascular function? A position paper. Arch Biochem Biophys 2008; 476: 102-6.
121. Mertens A, Holvoet P. Oxidized LDL and HDL: Antagonists in atherothrombosis. Faseb J 2001; 15: 2073-84.
122. Tijburg LB, Wiseman SA, Meijer GW, Weststrate JA. Effects of green tea, black tea and dietary lipophilic antioxidants on LDL oxidizability and atherosclerosis in hypercholesterolaemic rabbits. Atherosclerosis 1997; 135: 37-47.
123. Yamanaka N, Oda O, Nagao S. Green tea catechins such as (-)- epicatechin and (-)-epigallocatechin accelerate Cu2+-induced low density lipoprotein oxidation in propagation phase. FEBS Lett 1997; 401: 230-4.
124. Ishikawa T, Suzukawa M, Ito T, Yoshida H, Ayaori M, Nishiwaki M, et al. Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification. Am J Clin Nutr 1997; 66: 261-6.
125. Ohmori R, Iwamoto T, Tago M, Takeo T, Unno T, Itakura H, et al. Antioxidant activity of various teas against free radicals and LDL oxidation. Lipids 2005; 40: 849-53.
126. Chen XP, Xun KL, Wu Q, Zhang TT, Shi JS, Du GH. Oxidized low density lipoprotein receptor-1 mediates oxidized low density lipoprotein-induced apoptosis in human umbilical vein endothelial cells: role of reactive oxygen species. Vascul Pharmacol 2007; 47: 1-9.
127. Ou HC, Song TY, Yeh YC, Huang CY, Yang SF, Chiu TH, et al. EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. J Appl Physiol 2010; 108: 1745-56.
128. Sheng R, Gu ZL, Xie ML, Zhou WX, Guo CY. Epigallocatechin gallate protects H9c2 cardiomyoblasts against hydrogen dioxidesinduced apoptosis and telomere attrition. Eur J Pharmacol 2010; 641: 199-206.
129. Yang J, Han Y, Sun H, Chen C, He D, Guo J, et al. (-)- Epigallocatechin gallate suppresses proliferation of vascular smooth muscle cells induced by high glucose by inhibition of PKC and ERK1/2 signalings. J Agric Food Chem 2011; 59: 11483-90.
130. Won SM, Park YH, Kim HJ, Park KM, Lee WJ. Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Exp Mol Med 2006; 38: 525-34.
131. Han DW, Jung DY, Park JC, Cho HH, Hyon SH, Han DK. Underlying mechanism for suppression of vascular smooth muscle cells by green tea polyphenol EGCG released from biodegradable polymers for stent application. J Biomed Mater Res A 2010; 95: 424-33.
132. Chan CM, Huang JH, Chiang HS, Wu WB, Lin HH, Hong JY, et al. Effects of (-)-epigallocatechin gallate on RPE cell migration and adhesion. Mol Vis 2010; 16: 586-95.
133. Park JS, Kim MH, Chang HJ, Kim KM, Kim SM, Shin BA, et al. Epigallocatechin-3-gallate inhibits the PDGF-induced VEGF expression in human vascular smooth muscle cells via blocking PDGF receptor and Erk-1/2. Int J Oncol 2006; 29: 1247-52.
134. Weber AA, Neuhaus T, Skach RA, Hescheler J, Ahn HY, Schror K, et al. Mechanisms of the inhibitory effects of epigallocatechin-3 gallate on platelet-derived growth factor-BB-induced cell signaling and mitogenesis. Faseb J 2004; 18: 128-30.
135. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol 2012; 56: 232-44.
136. El Bedoui J, Oak MH, Anglard P, Schini-Kerth VB. Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1- MMP activity and MMP-2 expression. Cardiovasc Res 2005; 67: 317-25.
137. Maeda K, Kuzuya M, Cheng XW, Asai T, Kanda S, Tamaya-Mori N, et al. Green tea catechins inhibit the cultured smooth muscle cell invasion through the basement barrier. Atherosclerosis 2003; 166: 23-30.
138. Kim CH, Moon SK. Epigallocatechin-3-gallate causes the p21/WAF1-mediated G(1)-phase arrest of cell cycle and inhibits matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Arch Biochem Biophys 2005; 435: 264-72.
139. Gouni-Berthold I, Sachinidis A. Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseases. Curr Pharm Des 2004; 10: 1261-71.
140. Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin Proc 2006; 81: 59-68.
141. Kang WS, Lim IH, Yuk DY, Chung KH, Park JB, Yoo HS, et al. Antithrombotic activities of green tea catechins and (-)- epigallocatechin gallate. Thromb Res 1999; 96: 229-37.
142. Kang WS, Chung KH, Chung JH, Lee JY, Park JB, Zhang YH, et al. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase. J Cardiovasc Pharmacol 2001; 38: 875-84.
143. Son DJ, Cho MR, Jin YR, Kim SY, Park YH, Lee SH, et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids 2004; 71: 25-31.
144. Jin YR, Im JH, Park ES, Cho MR, Han XH, Lee JJ, et al. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity. J Cardiovasc Pharmacol 2008; 51: 45-54.
145. Matsumura K, Takayama H, Bae JY, Kurihara M, Tsutsumi S, Hyon SH. Preservation of platelets by adding epigallocatechin-3-ogallate to platelet concentrates. Cell Transplant 2009; 18: 521-8.
146. Lill G, Voit S, Schror K, Weber AA. Complex effects of different green tea catechins on human platelets. FEBS Lett 2003; 546: 265-70.
147. Yang JA, Choi JH, Rhee SJ. Effects of green tea catechin on phospholipase A2 activity and antithrombus in streptozotocin diabetic rats. J Nutr Sci Vitaminol (Tokyo) 1999; 45: 337-46.
148. Vezza R, Mezzasoma AM, Venditti G, Gresele P. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thromb Haemost 2002; 87: 114-21.
149. Sugatani J, Fukazawa N, Ujihara K, Yoshinari K, Abe I, Noguchi H, et al. Tea polyphenols inhibit acetyl-CoA:1-alkyl-sn-glycero-3- phosphocholine acetyltransferase (a key enzyme in plateletactivating factor biosynthesis) and platelet-activating factorinduced platelet aggregation. Int Arch Allergy Immunol 2004; 134: 17-28.
150. Senthil KV, Arulmathi K, Sundarapandiyan R, Kalaiselvi P. Attenuation of the inflammatory changes and lipid anomalies by epigallocatechin- 3-gallate in hypercholesterolemic diet fed aged rats. Exp Gerontol 2009; 44: 745-51.
151. Anandh Babu PV, Sabitha KE, Shyamaladevi CS. Green tea extract impedes dyslipidaemia and development of cardiac dysfunction in streptozotocin-diabetic rats. Clin Exp Pharmacol Physiol 2006; 33: 1184-9.
152. Babu PV, Sabitha KE, Shyamaladevi CS. Green tea impedes dyslipidemia, lipid peroxidation, protein glycation and ameliorates Ca2+ -ATPase and Na+/K+ -ATPase activity in the heart of streptozotocin- diabetic rats. Chem Biol Interact 2006; 162: 157-64.
153. Yang TT, Koo MW. Hypocholesterolemic effects of Chinese tea. Pharmacol Res 1997; 35: 505-12.
154. Roghani M, Baluchnejadmojarad T. Hypoglycemic and hypolipidemic effect and antioxidant activity of chronic epigallocatechingallate in streptozotocin-diabetic rats. Pathophysiology 2010; 17: 55-9.
155. Bursill CA, Abbey M, Roach PD. A green tea extract lowers plasma cholesterol by inhibiting cholesterol synthesis and upregulating the LDL receptor in the cholesterol-fed rabbit. Atherosclerosis 2007; 193: 86-93.
156. Koo SI, Noh SK. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. J Nutr Biochem 2007; 18: 179-83.
157. Wang S, Noh SK, Koo SI. Green tea catechins inhibit pancreatic phospholipase A(2) and intestinal absorption of lipids in ovariectomized rats. J Nutr Biochem 2006; 17: 492-8.
158. Raederstorff DG, Schlachter MF, Elste V, Weber P. Effect of EGCG on lipid absorption and plasma lipid levels in rats. J Nutr Biochem 2003; 14: 326-32.
159. Cuccioloni M, Mozzicafreddo M, Spina M, Tran CN, Falconi M, Eleuteri AM, et al. Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoA reductase. J Lipid Res 2011; 52: 897-907.
160. Abe I, Seki T, Umehara K, Miyase T, Noguchi H, Sakakibara J, et al. Green tea polyphenols: Novel and potent inhibitors of squalene epoxidase. Biochem Biophys Res Commun 2000; 268: 767-71.
161. Ikeda I, Imasato Y, Sasaki E, Nakayama M, Nagao H, Takeo T, et al. Tea catechins decrease micellar solubility and intestinal absorption of cholesterol in rats. Biochim Biophys Acta 1992; 1127: 141-6.
162. Shishikura Y, Khokhar S, Murray BS. Effects of tea polyphenols on emulsification of olive oil in a small intestine model system. J Agric Food Chem 2006; 54: 1906-13.
163. Chan PT, Fong WP, Cheung YL, Huang Y, Ho WK, Chen ZY. Jasmine green tea epicatechins are hypolipidemic in hamsters (Mesocricetus auratus) fed a high fat diet. J Nutr 1999; 129: 1094-101.
164. Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, Cole SP. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol 2001; 59: 1171-80.
165. Lee MS, Park JY, Freake H, Kwun IS, Kim Y. Green tea catechin enhances cholesterol 7alpha-hydroxylase gene expression in HepG2 cells. Br J Nutr 2008; 99: 1182-5.
166. Goto T, Saito Y, Morikawa K, Kanamaru Y, Nagaoka S. Epigallocatechin gallate changes mRNA expression level of genes involved in cholesterol metabolism in hepatocytes. Br J Nutr 2012; 107: 769-73.
167. Villarreal, F, Yamazaki, K.G., Taub, P.R., Maisel, A. Use of epicatechin and derivatives and salts therof for cardiac protection of ischemic myocardium and ameliorate adverse cardiac remodeling. US20110021466 A1 (2011).
168. Bukowski, JF, Walters, J. Tea-derived compositions and methods of using same for cardiovascular health. US20080081066A1 (2008).
169. Raederstorff, D, Weber, P., Wolfram, S. Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone. US20090221694A1 (2009).
170. Unno, T., Kakuda, T., Miyazawa, T., Nakagawa, K. Method for improving absorbability of epigallocatechin gallate, foods, drinks and food/drink materials using the same and method for producing the same. US20090047408A1 (2009).
171. Collin, P.D., Tilson, III, M.D. Methods for treating or preventing a vascular disease. US200801610099A1 (2008).
172. Sone T, Kuriyama S, Nakaya N, Hozawa A, Shimazu T, Nomura K, et al. Randomized controlled trial for an effect of catechinenriched green tea consumption on adiponectin and cardiovascular disease risk factors. Food Nutr Res 2011; 55.
173. Hirano R, Momiyama Y, Takahashi R, Taniguchi H, Kondo K, Nakamura H, et al. Comparison of green tea intake in Japanese patients with and without angiographic coronary artery disease. Am J Cardiol 2002; 90: 1150-3.
174. Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC, Schantz SP. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 1998; 7: 351-4.
175. Lee MJ, Wang ZY, Li H, Chen L, Sun Y, Gobbo S, et al. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev 1995; 4: 393-9.
176. Auger C, Mullen W, Hara Y, Crozier A. Bioavailability of polyphenon E flavan-3-ols in humans with an ileostomy. J Nutr 2008; 138: 1535S-42S.
177. Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 2005; 11: 4627-33.
178. Barras A, Mezzetti A, Richard A, Lazzaroni S, Roux S, Melnyk P, et al. Formulation and characterization of polyphenol-loaded lipid nanocapsules. Int J Pharm 2009; 379: 270-7.
179. Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009; 69: 1712-6.
180. Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. Nanolipidic particles improve the bioavailability and alphasecretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J Pharm 2010; 389: 207-12.
181. Hsu, S. Modified green tea polyphenol formulations. US2012076872A1 (2012).
182. Lambelet, P., Bortlik, K., Sabatier, M., Crespy, V., Williamson, G. Green tea extracts of improved bioavailability. EP2434911A1 (2012).
183. Townsend PA, Scarabelli TM, Pasini E, Gitti G, Menegazzi M, Suzuki H, et al. Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusioninduced apoptosis. Faseb J 2004; 18: 1621-3.
184. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 2005; 81: 243S-55S.
185. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple- dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9: 3312-9.